Veracyte, Inc.
- Open
- 59.10
- Day high
- 59.14
- Day low
- 56.45
- Prev close
- 59.30
- Volume
- 757K
- Mkt cap
- $4.5B
- P/E (TTM)
- 51.4
- EPS (TTM)
- $1.11
- P/B
- 3.4
- P/S
- 8.4
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$9.9M over the last 3 months (0 open-market buys, 11 sales)
- 🏛Institutions accumulating (13F)
Veracyte, Inc. (VCYT) is a Healthcare company listed on NASDAQ. The stock is up 115% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 11 sales (SEC Form 4).
Veracyte, Inc. (VCYT) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 6 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
VCYT earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $0.34 | $0.52 | +52.9% | $139M | +6.7% |
| Feb 25, 2026 | $0.41 | $0.51 | +23.9% | $141M | +3.6% |
| Aug 6, 2025 | $0.31 | $0.44 | +41.9% | $130M | +4.7% |
| May 7, 2025 | $0.20 | $0.31 | +55.0% | $114M | +3.2% |
| Feb 22, 2024 | $-0.07 | $-0.04 | +42.9% | $98M | +6.8% |
| May 4, 2023 | $-0.14 | $-0.11 | +21.4% | $82M | +8.7% |
| Feb 22, 2023 | $-0.15 | $-0.05 | +66.7% | $80M | +8.6% |
| Nov 2, 2022 | $-0.24 | $-0.12 | +50.0% | $76M | +13.8% |
| Aug 2, 2022 | $-0.21 | $-0.13 | +38.1% | $73M | +7.0% |
| May 3, 2022 | $-0.23 | $-0.20 | +13.0% | $68M | +9.5% |
| Feb 28, 2022 | $-0.14 | $-0.15 | -7.1% | $67M | +7.7% |
| Jul 29, 2021 | $-0.25 | $-0.13 | +48.0% | $55M | +0.0% |
VCYT insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 22, 2026 | EASTHAM KARINdirector | Sell | 3,200 | $52.78 |
| Jun 22, 2026 | EASTHAM KARINdirector | Sell | 529 | $53.55 |
| Jun 15, 2026 | Barr Eliavdirector | Grant | 5,272 | — |
| Jun 15, 2026 | Shafer David Brentdirector | Grant | 5,272 | — |
| Jun 15, 2026 | Holstein Jensdirector | Grant | 5,272 | — |
| Jun 15, 2026 | JONES EVAN/ FAdirector | Grant | 5,272 | — |
| Jun 15, 2026 | Miller Thomas F.director | Grant | 5,272 | — |
| Jun 15, 2026 | EPSTEIN ROBERT Sdirector | Grant | 5,272 | — |
| Jun 15, 2026 | EASTHAM KARINdirector | Grant | 5,272 | — |
| Jun 15, 2026 | Bhanji Munadirector | Grant | 5,272 | — |
| Jun 4, 2026 | Stapley Marcdirector, officer: Chief Executive Officer | Sell | 138,051 | $50.12 |
| Jun 4, 2026 | Chambers Rebeccaofficer: Chief Financial Officer | Tax | 3,693 | $47.80 |
| Jun 4, 2026 | McGuire Annieofficer: EVP, General Counsel | Sell | 1,400 | $49.31 |
| Jun 4, 2026 | Leite Johnofficer: Global Chief Commercial Off | Sell | 13,975 | $50.07 |
| Jun 4, 2026 | Febbo Phillip G.officer: Chief Scientific & Med Officer | Tax | 3,730 | $47.80 |
Source: VCYT SEC Form 4 filings, latest Jun 22, 2026. For informational purposes only — not investment advice.
See the full VCYT insider & 13F page →Veracyte, Inc. company profile
Overview
Veracyte, Inc. (NASDAQ:VCYT) is a molecular diagnostics company founded in 2006 and headquartered in South San Francisco, California. Originally incorporated as Calderome, Inc., the company changed its name to Veracyte in March 2008 and went public in October 2013. Veracyte has evolved from a single-product thyroid cancer diagnostics company into a diversified genomic testing platform serving multiple cancer types including prostate, breast, lung, and colon cancers.
Business
Veracyte operates in the molecular diagnostics industry, which uses genetic and genomic information to help physicians make better treatment decisions for cancer patients. The company's core business involves developing and commercializing genomic tests that analyze tissue samples to provide actionable information about cancer diagnosis, prognosis, and treatment planning. The company's primary products include several specialized diagnostic tests, each targeting specific cancer types: 1. Afirma Genomic Sequencing Classifier and Xpression Atlas (~25% of testing revenue) - These tests analyze thyroid nodules to determine whether they are benign or malignant, helping patients avoid unnecessary thyroid surgery. When a thyroid biopsy shows "indeterminate" results, these tests provide additional clarity by examining the genetic signature of the tissue. 2. Decipher Prostate tests (~65% of testing revenue) - Available for both biopsy and post-surgical specimens, these tests analyze the genetic profile of prostate cancer to predict how aggressive the cancer is likely to be. This helps urologists and oncologists determine whether patients need immediate treatment or can safely pursue active surveillance. 3. Prosigna Breast Cancer Assay (~5% of testing revenue) - This test evaluates the genetic signature of breast cancer tumors to predict the likelihood of cancer recurrence and help guide treatment decisions about chemotherapy. 4. Percepta Genomic Sequencing Classifier and Nasal Swab Test (in development) - These tests are designed to help diagnose lung cancer risk, with the nasal swab offering a less invasive screening option. 5. Envisia Genomic Classifier - Used to diagnose idiopathic pulmonary fibrosis and other interstitial lung diseases by analyzing lung tissue samples. 6. Immunoscore Colon Cancer test - Evaluates the immune response within colon cancer tumors to help predict patient outcomes. The company also generates revenue from product sales of testing instruments and reagents, as well as biopharma collaborations and licensing arrangements with companies like Johnson & Johnson and CareDx.
Revenue model
Veracyte generates revenue through multiple business models centered around its genomic testing platform. The primary revenue stream comes from diagnostic testing services, where healthcare providers order tests for their patients and Veracyte processes tissue samples in its laboratories, billing insurance companies or patients directly. Testing revenue accounts for approximately 95% of total revenue, with individual test prices typically ranging from several hundred to several thousand dollars depending on the complexity and clinical indication. The company's customers are primarily healthcare providers including urologists, endocrinologists, oncologists, and pathologists who order tests for their patients. Veracyte has built relationships with major health insurers and Medicare to secure reimbursement coverage, which is critical for adoption since these tests represent significant out-of-pocket costs for patients without coverage. Additional revenue streams include product sales of instruments and reagents to laboratories that perform some tests in-house, and biopharma partnerships where pharmaceutical companies license Veracyte's technology or collaborate on drug development programs. Several factors influence Veracyte's margins and profitability. Positive margin drivers include achieving economies of scale as test volumes grow, securing favorable reimbursement rates from commercial payers, expanding into higher-margin international markets through in-vitro diagnostic (IVD) products, and leveraging the company's existing laboratory infrastructure across multiple test types. Negative margin pressures come from ongoing investments in sales and marketing to drive adoption, research and development costs for new test development, potential reimbursement cuts from payers seeking to control healthcare costs, and competitive pressures from other diagnostic companies or alternative testing approaches. The company's transition from a growth-investment phase to profitability has been evident in recent quarters, with adjusted EBITDA margins improving from negative territory in 2022-2023 to over 20% by 2024.
Competitive moat
Veracyte's competitive moat is moderately strong but faces several vulnerabilities. The company's primary defensive advantages include its extensive clinical evidence base with dozens of peer-reviewed publications supporting each major test, established relationships with key opinion leaders in relevant medical specialties, and significant reimbursement coverage that creates switching costs for both physicians and patients. The company has also built proprietary genomic databases and analytical capabilities that would be difficult for competitors to replicate quickly. However, Veracyte's moat faces meaningful challenges. The molecular diagnostics space is highly competitive with well-funded competitors like Exact Sciences, Guardant Health, and traditional laboratory giants like Quest Diagnostics and LabCorp, all of whom have the resources to develop competing tests. Technological disruption represents a significant risk, as advances in liquid biopsy, artificial intelligence-powered pathology, or other diagnostic approaches could potentially render tissue-based genomic testing less relevant. The company's tests, while clinically validated, are not protected by strong intellectual property moats that would prevent competitors from developing similar approaches. Regulatory and reimbursement risks also threaten the moat, as changes in Medicare coverage policies or commercial payer attitudes toward genomic testing could significantly impact demand. The company's dependence on a relatively small number of high-volume tests (particularly Decipher and Afirma) creates concentration risk, and the loss of key reimbursement coverage or the emergence of superior competing tests could materially impact the business. While Veracyte has demonstrated success in building market-leading positions in specific niches, the sustainability of these positions depends on continuous innovation, clinical evidence generation, and successful navigation of an evolving healthcare reimbursement landscape.
Risks & safety
Strong financial position with minimal solvency risk and reasonable valuation metrics for a profitable growth company. • Cash and liquidity: $186 million in cash and short-term investments as of Q1 2025, with positive free cash flow generation of $64 million in 2024 • Debt level: Very low debt-to-equity ratio of 4.2%, minimal financial leverage • Profitability: Achieved profitability with $24 million net income in 2024, positive adjusted EBITDA margins above 20% • Current ratio: Strong liquidity position with current ratio of 5.1x • Valuation metrics: P/E ratio of 82x appears elevated but reflects recent profitability achievement; EV/EBITDA of 58x is high but reasonable for a growing healthcare technology company • Other considerations: Strong revenue growth trajectory (23% in 2024), diversified test portfolio reducing single-product risk, established reimbursement coverage providing revenue stability
Recent development
Over the past few years, Veracyte has executed several strategic initiatives to diversify its platform and expand market opportunities. The company's most significant development has been the rapid growth of its Decipher prostate cancer testing franchise, which has achieved 40% market penetration and 65% market share in the addressable market, with testing volumes growing 36% in 2024. The company is now expanding Decipher into the metastatic prostate cancer indication, which received technical assessment approval and is expected to launch fully in 2025. In thyroid cancer diagnostics, Veracyte has strengthened its Afirma franchise by securing expanded Medicare coverage for Bethesda V thyroid nodules and transitioning to a more advanced v2 transcriptome platform. The company has also been developing new market opportunities including the Percepta Nasal Swab test for lung cancer risk assessment through the NIGHTINGALE clinical study, though enrollment has faced challenges. A major strategic pivot has been Veracyte's entry into the Minimal Residual Disease (MRD) testing market through the acquisition of C2i Genomics in 2023. The company is developing its first MRD test for muscle invasive bladder cancer, expected to launch in the first half of 2026, representing a significant expansion into monitoring cancer recurrence after treatment. The company has also been pursuing international expansion through development of in-vitro diagnostic (IVD) versions of its tests, including submitting Prosigna for European regulatory approval and preparing IVD versions of Decipher and other tests for global markets. Additionally, Veracyte has been investing in digital pathology capabilities and exploring artificial intelligence applications, though these remain complementary to its core genomic testing approach rather than primary strategic focuses.
VCYT company profile · for informational purposes only — not investment advice.
Track VCYT with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free